Nurix Therapeutc-Rg
Clinical‑stage biopharma Nurix Therapeutics develops orally available BTK degraders (NX‑5948, NX‑2127) and CBL‑B inhibitor NX‑1607 for B‑cell cancers; in Phase I/II, backed by Gilead, Sanofi, and Pfizer collaborations.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 286
- HQ: San Francisco
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.